Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Merck
Dow
Baxter
Medtronic

Last Updated: December 9, 2021

DrugPatentWatch Database Preview

Litigation Details for CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA
The small molecule drug covered by the patents cited in this case is ⤷  Try it Free .

Details for CIPHER PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC.-FLORIDA (D.N.J. 2013)

Date Filed Document No. Description Snippet Link To Document
2015-04-09 105 Brief Construction Submission for U.S. Patent Nos. 8,367,102 and 7,435,427 (Attachments: # (1) Declaration…Construction Submission for U.S. Patent Nos. 8,367,102 and 7,435,427, # (2) Exhibit 1, # (3) Exhibit 2… 30 October 2015 1:13-cv-06502-RMB-AMD Patent None District Court, D. New Jersey External link to document
2015-04-20 109 Opinion five. 2 U.S. Patent No. 7,435,427, issued October 14, 2008. 3 U.S. Patent No. 8,367,102, issued…terms 1 of the two related patents, the ‘427 patent 2 and the ‘102 patent 3, both of which disclose…It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the invention to which…optimized.” (‘102 Patent, column 5, lines 20-25; ‘427 Patent, column 5 lines… solubilized” (‘102 Patent, column 3, lines 4-5; ‘427 Patent, column 2, lines 61-62) External link to document
2015-05-01 115 Motion to Seal Claim Construction Brief for U.S. Patent Nos. 8,367,102 and 7,435,427, # (4) Supplemental Declaration of… 30 October 2015 1:13-cv-06502-RMB-AMD Patent None District Court, D. New Jersey External link to document
2015-07-17 127 Stipulation and Proposed Order on United States Patent No. 8,367,102. (WALSH, LIZA) (Entered: 07/17/2015) … 30 October 2015 1:13-cv-06502-RMB-AMD Patent None District Court, D. New Jersey External link to document
2013-12-11 18 Answer to Complaint the expiration of United States Patent No. 8,367,102 (“the ‘102 patent”). Except as expressly admitted… before the expiration of U.S. Patent No. 8,367,102 (the “‘102 patent”). Counterclaim-Defendants further… B. Declaring that the claims of U.S. Patent No. 8,367,102 are invalid and/or not infringed; …infringed any valid claim of the ‘102 patent, and that the ‘102 patent is invalid and/or unenforceable. …expiration of the ‘102 patent was not an act of infringement of any valid claim of that patent, either directly External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Baxter
Mallinckrodt
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.